$12.60
0.68[5.70%]
At close: May 23
$12.60
0[0.00%]
After Hours: 9:16AM EDT
Cidara Therapeutics
(NASDAQ:CDTX)Cidara Therapeutics Stock (NASDAQ:CDTX), Analyst Ratings, Price Targets, Predictions
Cidara Therapeutics Inc has a consensus price target of $13.17, established from looking at the 28 latest analyst ratings. The last 3 analyst ratings were released from Needham, WBB Securities, and Needham on May 16, 2024, April 25, 2024, and April 25, 2024. With an average price target of $30 between Needham, WBB Securities, and Needham, there's an implied 138.10% upside for Cidara Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
WBB Securities
Cantor Fitzgerald
HC Wainwright & Co.
Aegis Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cidara Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 98.41% | Needham | Joseph Stringer | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 217.46% | WBB Securities | Stephen Brozak | → $40 | Maintains | Strong Buy | Get Alert |
| 04/25/2024 | Buy Now | 98.41% | Needham | Joseph Stringer | $3 → $25 | Maintains | Buy | Get Alert |
| 04/25/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 04/23/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen | — | Reiterates | → Overweight | Get Alert |
| 04/08/2024 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | $120 → $120 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | -76.19% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | -76.19% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/07/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | -76.19% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | → Buy | Get Alert |
| 08/01/2023 | Buy Now | -60.32% | Cantor Fitzgerald | Louise Chen | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | -76.19% | Needham | Joseph Stringer | → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | Buy Now | -76.19% | Needham | Joseph Stringer | → $60 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | → $120 | Reiterates | → Buy | Get Alert |
| 03/23/2023 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | $130 → $120 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | -60.32% | Cantor Fitzgerald | Louise Chen | → $100 | Reiterates | → Overweight | Get Alert |
| 03/01/2023 | Buy Now | -48.41% | HC Wainwright & Co. | Ed Arce | → $130 | Reiterates | → Buy | Get Alert |
| 01/25/2023 | Buy Now | -48.41% | HC Wainwright & Co. | Ed Arce | $120 → $130 | Maintains | Buy | Get Alert |
| 05/12/2022 | Buy Now | -52.38% | HC Wainwright & Co. | Ed Arce | $150 → $120 | Maintains | Buy | Get Alert |
| 09/22/2021 | Buy Now | -36.51% | Aegis Capital | Nathan Weinstein | $180 → $160 | Maintains | Buy | Get Alert |
| 09/22/2021 | Buy Now | — | WBB Securities | Steve Brozak | — | Upgrade | Buy → Strong Buy | Get Alert |
FAQ
What is the target price for Cidara Therapeutics (CDTX)?
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by Needham on May 16, 2024. The analyst firm set a price target for $25.00 expecting CDTX to rise to within 12 months (a possible 98.41% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by Needham, and Cidara Therapeutics reiterated their buy rating.
When was the last upgrade for Cidara Therapeutics (CDTX)?
The last upgrade for Cidara Therapeutics Inc happened on September 22, 2021 when WBB Securities raised their price target to N/A. WBB Securities previously had a buy for Cidara Therapeutics Inc.
When was the last downgrade for Cidara Therapeutics (CDTX)?
There is no last downgrade for Cidara Therapeutics.
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $25.00. The current price Cidara Therapeutics (CDTX) is trading at is $12.60, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.